YPC‐22026 (50-100 mg/kg; i.p; on days 1, 2, 3, 8, 9, 12, and 16) significantly inhibits the growth of tumors in the HCT116 xenograft model[1].
In the PC‐3 xenograft model, YPC‐22026 (75 mg/kg; ip) significantly decreases in the intratumoral expression levels of all ZNF143 target genes, RAD51, PLK1, and Survivin[1].
| Animal Model: | Six‐week‐old male BALB/c nude mice injected with HCT116 cells[1] |
| Dosage: | 50 mg/kg and 100 mg/kg |
| Administration: | i.p; on days 1, 2, 3, 8, 9, 12, and 16 (50 mg/kg ); on days 1, 2, 3, 12, and 16 (100 mg/kg) |
| Result: | Significantly inhibited the growth of tumors. |
